Risk factors and treatment of brain metastasis in patients with small cell lung
PUBLISHED: 2015-11-26  408 total views, 1 today

Bo Li1, Zhengming Wang2, Suozhu Sun3, Bing Liu4, Zhenzhen Li4Kaijin Wang4, Xifan Wang4, Wei Xu4, Jiaomin Chen4, Huoming Chen4

1Department of Oncology, The SecondArtillery General Hospital PLA, 2Department of Imaging,The Second Artillery General Hospital PLA, 3Department of Pathology,The Second Artillery General Hospital PLA, 4Department of MedicalOncology of PLA Cancer Center, The Second Artillery General Hospital PLA

Objective:To explore the risk factors of brainmetastasis (BM) and the role of treatment in patients with small cell lungcancer. Method: Clinical data of 263 prophylactic cranial irradiation(PCI) naïve patients of small cell lung cancer who were diagnosed betweenJanuary 2003 and March 2014 were analyzed retrospectively. Factors includinggender (male vs female), age (<60ys vs ≥60ys), stage, smoking status (nevervscurrent) were analyzed. Furthermore, the influence of treatment mortalities onbrain-metastasis-free survival (BMFS) and post-brain-metastasis survival (PBMS)were also studied. Result: Patients with stage II-IV at diagnosis hadsignificantly higher incidence of BM compared with those with stage I (P=0.01).Those with T1/2 (P=0.05) and never-smoking history (P=0.06) hadshorter BMFS. In patients with stage II disease at diagnosis, there was atendency that those received chemotherapy and radiotherapy had longer BMFScompared with those received chemotherapy only (21months vs 12months, P=0.06).While the difference between patients received concomitant and sequential chemoradiotherapywas comparable (P=0.63). Furthermore, in stage II patients who receivedchemotherapy only, those obtained complete remission and partialremission hadsignificantly longer BMFS (12 months vs 3 months, P<0.001). When BMoccurred, radiation to the brain could significantly improve PBMS (P<0.001).Although those received both whole brain radiation therapy (WBRT) andstereotactic radiosurgery (SRS) had longer PBMS than those received either WBRTor SRS, the difference did not reach the significant level (P=0.1).Post-BM chemotherapy could prolong the PBMS (P=0.05). However, inpatients received WBRT and/or SRS, additional chemotherapy did not furtherimproved the PBMS (P=0.2). Conclusion: Patients with stage II-IVdisease had significantly higher incidence of BM. Chmoradiotherapy couldprolongthe BMFS in patients with stage II disease. Radiotherapy to the brain couldsignificantly improve PBMS, however, additional chemotherapy failed to furtherimprove PBMS.


Key Words: small cell lung cancer  brain metastasis  surgery

Copyright © 1998 - 2019 Chinese Society of Clinical Oncology(CSCO). All Rights Reserved

京公网安备 11010502031031号

Contact Us



Phone:86(10)67726451 (Beijing)

86(25)84547290 (Nanjing)